In this work, we provide the first link between the expression of four putative markers SCCC and clinical outcomes in patients with cervical cancer. Previous studies have shown that cfc are responsible for the high rate of drug resistance and tumor relapse. Clinical and experimental studies have provided evidence of the relationship between the different phenotypes of CPSS and resistance to chemotherapeutic drugs. Our results suggest that the expression of markers of csc MSI1, ALDH1, sox2 and CD49f have been increased in the CCHC tissue and their expression are related to clinical survival in cancer patients undergoing cervical postoperative chemotherapy , suggesting an important role of these markers for predicting the clinical prognosis in cervical cancer. Surprisingly, we found that the expression of CSC markers showed no association with age, tumor stage, tumor size, or tumor differentiation, while expression Sox2 was significantly correlated with the tumor size. Numerous recent studies investigating the ALDH1 gene or protein indicate its impact on the clinical outcome of patients with malignant tumors.
Our investigation revealed that this strong expression ALDH1 was an independent predictor of recurrence and overall survival in patients with SCLC. The same finding was also applied for another potential marker ccsc sox2. In this study, we found that the regulation of sox2 predict overall survival and recurrence-free for poor patients of SCLC. Relatively few studies have evaluated the role of MSI1 in chemoresistance. In this study, we document a time of overall survival without poor again with a strong expression of MSI1 in univariate but not multivariate analysis of survival times, indicating that the role of poor prognosis MSI1 may be secondary to their association with other established prognostic criteria.
In total, these studies suggest that increasing ALDH1, sox2 MSI1 and expression are related to the progression and may be linked to chemoresistance cscc. Interestingly, it was found that the expression CD49f was increased in tissues whereas SCLC high expression of CD49f has been associated with a favorable prognosis of the patients. The results suggest that the expression CD49f is related to a reduction of drug resistance in cervical cancer. The unexpected discovery that CD49f expression was correlated with improved clinical results suggest that all CSC markers characterize the population chemoresistant cells and that the prognostic role of CD49f could be a specific and diversified fabric in various cancers. An important conclusion of this investigation is that tumors MSI1 high and low expression of CD49f had the poorest prognosis, whereas tumors with lack of MSI1 CD49f overexpression and had the best prognosis.
The results indicate the importance of such a subpopulation to predict prognosis and chemosensitivity of patients with cervical cancer. Targeting this cell population with new pharmaceutical agents may be effective for the treatment of chemoresistant tumors of the neck. In conclusion, our study provides the first clinical evidence that CSC markers are associated with the clinical prognosis of patients with SCLC. High expression of MSI1, ALDH1 and sox2, and low expression of CD49f predict a poor prognosis for patients with cancer of the cervix receiving postoperative chemotherapy. Our results can be of great value in the development of personalized therapies for patients with cancer of the cervix. cancer stem cell markers correlate with histopathologic variables. Th YNZ and were responsible for the design of this study.
Th, and CJT gk performed the experiments and drafted the manuscript. WJZ participated in the collection and analysis of data. State Key Laboratory of Oncology in South China University Cancer Center Sun Yat-sen, the center of collaborative innovation for cancer medicine. Department of Urology, Hospital of the union, Tongji Medical College, Huazhong University of Science and Technology. Duyn, van Eijkeren m, kENTER g, k Zwinderman, Ansink a.